643 related articles for article (PubMed ID: 9854115)
1. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
[TBL] [Abstract][Full Text] [Related]
2. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
[TBL] [Abstract][Full Text] [Related]
3. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
[TBL] [Abstract][Full Text] [Related]
4. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy.
Mayer KH; Boswell S; Goldstein R; Lo W; Xu C; Tucker L; DePasquale MP; D'Aquila R; Anderson DJ
Clin Infect Dis; 1999 Jun; 28(6):1252-9. PubMed ID: 10451162
[TBL] [Abstract][Full Text] [Related]
5. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.
Imamichi H; Crandall KA; Natarajan V; Jiang MK; Dewar RL; Berg S; Gaddam A; Bosche M; Metcalf JA; Davey RT; Lane HC
J Infect Dis; 2001 Jan; 183(1):36-50. PubMed ID: 11106537
[TBL] [Abstract][Full Text] [Related]
7. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
8. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
Vitone F; Gibellini D; Schiavone P; Re MC
J Clin Virol; 2005 Jul; 33(3):194-200. PubMed ID: 15911440
[TBL] [Abstract][Full Text] [Related]
9. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
Celum CL; Buchbinder SP; Donnell D; Douglas JM; Mayer K; Koblin B; Marmor M; Bozeman S; Grant RM; Flores J; Sheppard HW
J Infect Dis; 2001 Jan; 183(1):23-35. PubMed ID: 11106536
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
11. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
Günthard HF; Wong JK; Spina CA; Ignacio C; Kwok S; Christopherson C; Hwang J; Haubrich R; Havlir D; Richman DD
J Infect Dis; 2000 Feb; 181(2):522-31. PubMed ID: 10669335
[TBL] [Abstract][Full Text] [Related]
12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
13. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.
Si-Mohamed A; Kazatchkine MD; Heard I; Goujon C; Prazuck T; Aymard G; Cessot G; Kuo YH; Bernard MC; Diquet B; Malkin JE; Gutmann L; Bélec L
J Infect Dis; 2000 Jul; 182(1):112-22. PubMed ID: 10882588
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.
Pereira AS; Kashuba AD; Fiscus SA; Hall JE; Tidwell RR; Troiani L; Dunn JA; Eron JJ; Cohen MS
J Infect Dis; 1999 Dec; 180(6):2039-43. PubMed ID: 10558966
[TBL] [Abstract][Full Text] [Related]
15. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma.
Lorello G; la Porte C; Pilon R; Zhang G; Karnauchow T; MacPherson P
HIV Med; 2009 Oct; 10(9):548-54. PubMed ID: 19515092
[TBL] [Abstract][Full Text] [Related]
16. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections.
Taylor S; Sadiq ST; Weller I; Kaye S; Workman J; Cane PA; Bennett J; Copas AJ; Drake SM; Pillay D
Antivir Ther; 2003 Oct; 8(5):479-83. PubMed ID: 14640396
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 DNA and RNA kinetics in primary HIV infection.
Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
[TBL] [Abstract][Full Text] [Related]
20. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
Eron JJ; Smeaton LM; Fiscus SA; Gulick RM; Currier JS; Lennox JL; D'Aquila RT; Rogers MD; Tung R; Murphy RL
J Infect Dis; 2000 May; 181(5):1622-8. PubMed ID: 10783117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
